nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.01.2009 | Review

Pathogenesis of malignant pleural mesothelioma and the role of environmental and genetic factors

verfasst von: Shoshana J. Weiner, Siyamek Neragi-Miandoab

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 1/2009

Einloggen, um Zugang zu erhalten

Abstract

Background

Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor for which no effective therapy exists despite the discovery of many possible molecular and genetic targets. The late stage of MPM diagnosis and the long latency that exist between some exposures and diagnosis have made it difficult to comprehensively evaluate the role of risk factors and their downstream molecular effects.

Methods

This manuscript is a review of current literature about the pathogenesis of malignant mesothelioma. In this overview, current published studies concerning pathogenesis of malignant mesothelioma are reviewed, with insights into its etiology and pathogenesis. We searched pubmed using the following subjects: mesothelioma, radiation, genetics, pediatric malignant mesothelioma, SV40 virus, and growth factors. We selected 350 valuable articles of which 152 sources were used to complete this review.

Conclusion

Many risk factors for MPM development have been recognized including environmental exposures, genetic susceptibility, viral contamination, and radiation. In this review, we discuss the current molecular and genetic contributors to MPM pathogenesis and the risk factors associated with these carcinogenic processes.

Abutaily AS, Collins JE, Roche WR (2003) Cadherins, catenins and APC in pleural malignant mesothelioma. J Pathol 201(3):355–362. doi:10.1002/path.1458 PubMed

Adams VI, Unni KK (1984) Diffuse malignant mesothelioma of pleura: diagnostic criteria based on an autopsy study. Am J Clin Pathol 82(1):15–23PubMed

Adamson IY, Bakowska J (2001) KGF and HGF are growth factors for mesothelial cells in pleural lavage fluid after intratracheal asbestos. Exp Lung Res 27(7):605–616. doi:10.1080/019021401753181854 PubMed

Altomare DA, Vaslet CA, Skele KL, De Rienzo A, Devarajan K, Jhanwar SC et al (2005) A mouse model recapitulating molecular features of human mesothelioma. Cancer Res 65(18):8090–8095. doi:10.1158/0008-5472.CAN-05-2312 PubMed

Anderson KA, Hurley WC, Hurley BT, Ohrt DW (1985) Malignant pleural mesothelioma following radiotherapy in a 16-year-old boy. Cancer 56(2):273–276. doi:10.1002/1097-0142(19850715)56:2<273::AID-CNCR2820560212>3.0.CO;2-0PubMed

Antman KH, Ruxer RL Jr, Aisner J, Vawter G (1984) Mesothelioma following Wilms’ tumor in childhood. Cancer 54(2):367–369. doi:10.1002/1097-0142(19840715)54:2<367::AID-CNCR2820540232>3.0.CO;2-YPubMed

Apostolou S, De Rienzo A, Murthy SS, Jhanwar SC, Testa JR (1999) Absence of BCL10 mutations in human malignant mesothelioma. Cell 97(6):684–686. doi:10.1016/S0092-8674(02)09765-9 discussion 686–688PubMed

Ascoli V, Cavone D, Merler E, Barbieri PG, Romeo L, Nardi F et al (2007) Mesothelioma in blood related subjects: report of 11 clusters among 1954 Italy cases and review of the literature. Am J Ind Med 50(5):357–369. doi:10.1002/ajim.20451 PubMed

Asplund T, Versnel MA, Laurent TC, Heldin P (1993) Human mesothelioma cells produce factors that stimulate the production of hyaluronan by mesothelial cells and fibroblasts. Cancer Res 53(2):388–392PubMed

Ault JG, Cole RW, Jensen CG, Jensen LC, Bachert LA, Rieder CL (1995) Behavior of crocidolite asbestos during mitosis in living vertebrate lung epithelial cells. Cancer Res 55(4):792–798PubMed

Aung W, Hasegawa S, Furukawa T, Saga T (2007) Potential role of ferritin heavy chain in oxidative stress and apoptosis in human mesothelial and mesothelioma cells: implications for asbestos-induced oncogenesis. Carcinogenesis 28(9):2047–2052PubMed

Austin MB, Fechner RE, Roggli VL (1986) Pleural malignant mesothelioma following Wilms’ tumor. Am J Clin Pathol 86(2):227–230PubMed

Babcock TL, Powell DH, Bothwell RS (1976) Radiation-induced peritoneal mesothelioma. J Surg Oncol 8(5):369–372. doi:10.1002/jso.2930080503 PubMed

Balsara BR, Bell DW, Sonoda G, De Rienzo A, du Manoir S, Jhanwar SC et al (1999) Comparative genomic hybridization and loss of heterozygosity analyses identify a common region of deletion at 15q11.1–15 in human malignant mesothelioma. Cancer Res 59(2):450–454PubMed

Barbanti-Brodano G, Sabbioni S, Martini F, Negrini M, Corallini A, Tognon M (2004) Simian virus 40 infection in humans and association with human diseases: results and hypotheses. Virology 318(1):1–9. doi:10.1016/j.virol.2003.09.004 PubMed

Batra S, Shi Y, Kuchenbecker KM, He B, Reguart N, Mikami I et al (2006) Wnt inhibitory factor-1, a Wnt antagonist, is silenced by promoter hypermethylation in malignant pleural mesothelioma. Biochem Biophys Res Commun 342(4):1228–1232. doi:10.1016/j.bbrc.2006.02.084 PubMed

Battifora H (1989) The Pleura. In: Sternberg SS (ed) Diagnostic Surgical Pathology. Oxford University Press, Oxford, pp 828

Bertino P, Marconi A, Palumbo L, Bruni BM, Barbone D, Germano S et al (2007) Erionite and asbestos differently cause transformation of human mesothelial cells. Int J Cancer 121(1):12–20. doi:10.1002/ijc.22687 PubMed

Bianchi C, Bianchi T (2007) Malignant mesothelioma: global incidence and relationship with asbestos. Ind Health 45(3):379–387. doi:10.2486/indhealth.45.379 PubMed

Bianchi C, Brollo A, Ramani L, Bianchi T, Giarelli L (2004) Familial mesothelioma of the pleura—a report of 40 cases. Ind Health 42(2):235–239. doi:10.2486/indhealth.42.235 PubMed

Bjorkqvist AM, Tammilehto L, Anttila S, Mattson K, Knuutila S (1997) Recurrent DNA copy number changes in 1q, 4q, 6q, 9p, 13q, 14q and 22q detected by comparative genomic hybridization in malignant mesothelioma. Br J Cancer 75(4):523–527PubMed

Bocchetta M, Di Resta I, Powers A, Fresco R, Tosolini A, Testa JR et al (2000) Human mesothelial cells are unusually susceptible to simian virus 40-mediated transformation and asbestos cocarcinogenicity. Proc Natl Acad Sci USA 97(18):10214–10219. doi:10.1073/pnas.170207097 PubMed

Bocchetta M, Miele L, Pass HI, Carbone M (2003) Notch-1 induction, a novel activity of SV40 required for growth of SV40-transformed human mesothelial cells. Oncogene 22(1):81–89. doi:10.1038/sj.onc.1206097 PubMed

Boutin C, Schlesser M, Frenay C, Astoul P (1998) Malignant pleural mesothelioma. Eur Respir J 12(4):972–981. doi:10.1183/09031936.98.12040972 PubMed

Butel JS, Jafar S, Stewart AR, Lednicky JA (1998) Detection of authentic SV40 DNA sequences in human brain and bone tumours. Dev Biol Stand 94:23–32PubMed

Cacciotti P, Libener R, Betta P, Martini F, Porta C, Procopio A et al (2001) SV40 replication in human mesothelial cells induces HGF/Met receptor activation: a model for viral-related carcinogenesis of human malignant mesothelioma. Proc Natl Acad Sci USA 98(21):12032–12037. doi:10.1073/pnas.211026798 PubMed

Cacciotti P, Strizzi L, Vianale G, Iaccheri L, Libener R, Porta C et al (2002) The presence of simian-virus 40 sequences in mesothelioma and mesothelial cells is associated with high levels of vascular endothelial growth factor. Am J Respir Cell Mol Biol 26(2):189–193PubMed

Cacciotti P, Barbone D, Porta C, Altomare DA, Testa JR, Mutti L et al (2005) SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure. Cancer Res 65(12):5256–5262. doi:10.1158/0008-5472.CAN-05-0127 PubMed

Cahan WG, Woodard HQ, Higinbotham NL, Stewart FW, Coley BL (1998) Sarcoma arising in irradiated bone: report of eleven cases. 1948. Cancer 82(1):8–34. doi:10.1002/(SICI)1097-0142(19980101)82:1<8::AID-CNCR3>3.0.CO;2-WPubMed

Carbone M (1999) Simian virus 40 and human tumors: it is time to study mechanisms. J Cell Biochem 76(2):189–193. doi:10.1002/(SICI)1097-4644(20000201)76:2<189::AID-JCB3>3.0.CO;2-JPubMed

Carbone M, Pass HI (2002) Re: debate on the link between SV40 and human cancer continues. J Natl Cancer Inst 94(3):229–230PubMed

Carbone M, Pass HI, Rizzo P, Marinetti M, Di Muzio M, Mew DJ et al (1994) Simian virus 40-like DNA sequences in human pleural mesothelioma. Oncogene 9(6):1781–1790PubMed

Carbone M, Kratzke RA, Testa JR (2002) The pathogenesis of mesothelioma. Semin Oncol 29(1):2–17. doi:10.1053/sonc.2002.30227 PubMed

Cavazza A, Travis LB, Travis WD, Wolfe JT 3rd, Foo ML, Gillespie DJ et al (1996) Post-irradiation malignant mesothelioma. Cancer 77(7):1379–1385. doi:10.1002/(SICI)1097-0142(19960401)77:7<1379::AID-CNCR24>3.0.CO;2-YPubMed

Choe N, Tanaka S, Kagan E (1998) Asbestos fibers and interleukin-1 upregulate the formation of reactive nitrogen species in rat pleural mesothelial cells. Am J Respir Cell Mol Biol 19(2):226–236PubMed

Coffin CM, Dehner LP (1992) Mesothelial and related neoplasms in children and adolescents: a clinicopathologic and immunohistochemical analysis of eight cases. Pediatric Pathol 12(3):333–347

Comba P, Gianfagna A, Paoletti L (2003) Pleural mesothelioma cases in Biancavilla are related to a new fluoro-edenite fibrous amphibole. Arch Environ Health 58(4):229–232. doi:10.3200/AEOH.58.4.229-232 PubMed

Corson JM (1997) Pathology of diffuse malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 9(4):347–355PubMed

Cristaudo A, Foddis R, Vivaldi A, Buselli R, Gattini V, Guglielmi G et al (2005) SV40 enhances the risk of malignant mesothelioma among people exposed to asbestos: a molecular epidemiologic case-control study. Cancer Res 65(8):3049–3052PubMed

De Rienzo A, Jhanwar SC, Testa JR (2000) Loss of heterozygosity analysis of 13q and 14q in human malignant mesothelioma. Genes Chromosomes Cancer 28(3):337–341. doi:10.1002/1098-2264(200007)28:3<337::AID-GCC12>3.0.CO;2-BPubMed

Demirag F, Unsal E, Yilmaz A, Caglar A (2005) Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma. Chest 128(5):3382–3387. doi:10.1378/chest.128.5.3382 PubMed

Destro A, Ceresoli GL, Falleni M, Zucali PA, Morenghi E, Bianchi P et al (2006) EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations. Lung Cancer 51(2):207–215. doi:10.1016/j.lungcan.2005.10.016 PubMed

Dewar A, Valente M, Ring NP, Corrin B (1987) Pleural mesothelioma of epithelial type and pulmonary adenocarcinoma: an ultrastructural and cytochemical comparison. J Pathol 152(4):309–316. doi:10.1002/path.1711520409 PubMed

Dhaene K, Wauters J, Weyn B, Timmermans JP, van Marck E (2000) Expression profile of telomerase subunits in human pleural mesothelioma. J Pathol 190(1):80–85. doi:10.1002/(SICI)1096-9896(200001)190:1<80::AID-PATH498>3.0.CO;2-7PubMed

Dianzani I, Gibello L, Biava A, Giordano M, Bertolotti M, Betti M et al (2006) Polymorphisms in DNA repair genes as risk factors for asbestos-related malignant mesothelioma in a general population study. Mutat Res 599(1–2):124–134. doi:10.1016/j.mrfmmm.2006.02.005 PubMed

Edwards JG, McLaren J, Jones JL, Waller DA, O’Byrne KJ (2003) Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura. Br J Cancer 88(10):1553–1559. doi:10.1038/sj.bjc.6600920 PubMed

Engels EA, Katki HA, Nielsen NM, Winther JF, Hjalgrim H, Gjerris F et al (2003) Cancer incidence in Denmark following exposure to poliovirus vaccine contaminated with simian virus 40. J Natl Cancer Inst 95(7):532–539PubMedCrossRef

Foddis R, De Rienzo A, Broccoli D, Bocchetta M, Stekala E, Rizzo P et al (2002) SV40 infection induces telomerase activity in human mesothelial cells. Oncogene 21(9):1434–1442. doi:10.1038/sj.onc.1205203 PubMed

Fraire AE, Cooper S, Greenberg SD, Buffler P, Langston C (1988) Mesothelioma of childhood. Cancer 62(4):838–847. doi:10.1002/1097-0142(19880815)62:4<838::AID-CNCR2820620433>3.0.CO;2-9PubMed

Gilks B, Hegedus C, Freeman H, Fratkin L, Churg A (1988) Malignant peritoneal mesothelioma after remote abdominal radiation. Cancer 61(10):2019–2021. doi:10.1002/1097-0142(19880515)61:10<2019::AID-CNCR2820611015>3.0.CO;2-KPubMed

Griffiths DJ, Nicholson AG, Weiss RA (1998) Detection of SV40 sequences in human mesothelioma. Dev Biol Stand 94:127–136PubMed

Gulumian M, van Wyk JA (1987) Hydroxyl radical production in the presence of fibres by a Fenton-type reaction. Chem Biol Interact 62(1):89–97. doi:10.1016/0009-2797(87)90081-0 PubMed

Hansen K, Mossman BT (1987) Generation of superoxide (O2-.) from alveolar macrophages exposed to asbestiform and nonfibrous particles. Cancer Res 47(6):1681–1686PubMed

Harvey P, Warn A, Dobbin S, Arakaki N, Daikuhara Y, Jaurand MC et al (1998) Expression of HGF/SF in mesothelioma cell lines and its effects on cell motility, proliferation and morphology. Br J Cancer 77(7):1052–1059PubMed

He B, Lee AY, Dadfarmay S, You L, Xu Z, Reguart N et al (2005) Secreted frizzled-related protein 4 is silenced by hypermethylation and induces apoptosis in beta-catenin-deficient human mesothelioma cells. Cancer Res 65(3):743–748PubMed

Hill JK, Heitmiller RF 2nd, Askin FB, Kuhlman JE (1997) Localized benign pleural mesothelioma arising in a radiation field. Clin Imaging 21(3):189–194. doi:10.1016/S0899-7071(96)00024-1 PubMed

Hirano H, Tsuji M, Kizaki T, Sashikata T, Yoshi Y, Okada Y et al (2002) Expression of matrix metalloproteinases, tissue inhibitors of metalloproteinase, collagens, and Ki67 antigen in pleural malignant mesothelioma: an immunohistochemical and electron microscopic study. Med Electron Microsc 35(1):16–23. doi:10.1007/s007950200002 PubMed

Hofmann J, Mintzer D, Warhol MJ (1994) Malignant mesothelioma following radiation therapy. Am J Med 97(4):379–382. doi:10.1016/0002-9343(94)90307-7 PubMed

Hubbard R (1997) The aetiology of mesothelioma: are risk factors other than asbestos exposure important? Thorax 52(6):496–497PubMedCrossRef

Huncharek M (2002) Non-asbestos related diffuse malignant mesothelioma. Tumori 88(1):1–9PubMed

Hussussian CJ, Mackinnon SE (1999) Postradiation neural sheath sarcoma of the brachial plexus: a case report. Ann Plast Surg 43(3):313–317. doi:10.1097/00000637-199909000-00017 PubMed

Huuskonen MS, Karjalainen A, Tossavainen A, Rantanen J (1995) Asbestos and cancer in Finland. Med Lav 86(5):426–434PubMed

Illei PB, Rusch VW, Zakowski MF, Ladanyi M (2003) Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin Cancer Res 9(6):2108–2113PubMed

Inoue YZ, Frassica FJ, Sim FH, Unni KK, Petersen IA, McLeod RA (2000) Clinicopathologic features and treatment of postirradiation sarcoma of bone and soft tissue. J Surg Oncol 75(1):42–50. doi:10.1002/1096-9098(200009)75:1<42::AID-JSO8>3.0.CO;2-GPubMed

Ismail-Khan R, Robinson LA, Williams CC Jr, Garrett CR, Bepler G, Simon GR (2006) Malignant pleural mesothelioma: a comprehensive review. Cancer Control 13(4):255–263PubMed

Jagadeeswaran R, Ma PC, Seiwert TY, Jagadeeswaran S, Zumba O, Nallasura V et al (2006) Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res 66(1):352–361. doi:10.1158/0008-5472.CAN-04-4567 PubMed

Jaurand MC (1991) Observations on the carcinogenicity of asbestos fibers. Ann N Y Acad Sci 643:258–270. doi:10.1111/j.1749-6632.1991.tb24470.x PubMed

Jimenez LA, Zanella C, Fung H, Janssen YM, Vacek P, Charland C et al (1997) Role of extracellular signal-regulated protein kinases in apoptosis by asbestos and H2O2. Am J Physiol 273(5 Pt 1):L1029–L1035PubMed

Kamp DW, Israbian VA, Preusen SE, Zhang CX, Weitzman SA (1995) Asbestos causes DNA strand breaks in cultured pulmonary epithelial cells: role of iron-catalyzed free radicals. Am J Physiol 268(3 Pt 1):L471–L480PubMed

Kawashima A, Libshitz HI, Lukeman JM (1990) Radiation-induced malignant pleural mesothelioma. Can Assoc Radiol J 41(6):384–386PubMed

Kindler HL (2004) Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma. Lung Cancer 45(Suppl 1):S125–S127. doi:10.1016/j.lungcan.2004.04.022 PubMed

Kitamura F, Araki S, Suzuki Y, Yokoyama K, Tanigawa T, Iwasaki R (2002) Assessment of the mutations of p53 suppressor gene and Ha- and Ki-ras oncogenes in malignant mesothelioma in relation to asbestos exposure: a study of 12 American patients. Ind Health 40(2):175–181. doi:10.2486/indhealth.40.175 PubMed

Klein G, Powers A, Croce C (2002) Association of SV40 with human tumors. Oncogene 21(8):1141–1149. doi:10.1038/sj.onc.1205173 PubMed

Kops SP (2000) Oral polio vaccine and human cancer: a reassessment of SV40 as a contaminant based upon legal documents. Anticancer Res 20(6C):4745–4749PubMed

Kops GJ, Weaver BA, Cleveland DW (2005) On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev 5(10):773–785

Kumar K, Rahman Q, Schipper H, Matschegewski C, Schiffmann D, Papp T (2005) Mutational analysis of 9 different tumour-associated genes in human malignant mesothelioma cell lines. Oncol Rep 14(3):743–750PubMed

Kumar-Singh S, Segers K, Rodeck U, Backhovens H, Bogers J, Weyler J et al (1997) WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis. J Pathol 181(1):67–74. doi:10.1002/(SICI)1096-9896(199701)181:1<67::AID-PATH723>3.0.CO;2-ZPubMed

Landi S, Gemignani F, Neri M, Barale R, Bonassi S, Bottari F et al (2007) Polymorphisms of glutathione-S-transferase M1 and manganese superoxide dismutase are associated with the risk of malignant pleural mesothelioma. Int J Cancer 120(12):2739–2743. doi:10.1002/ijc.22590 PubMed

Langerak AW, Williamson KA, Miyagawa K, Hagemeijer A, Versnel MA, Hastie ND (1995) Expression of the Wilms’ tumor gene WT1 in human malignant mesothelioma cell lines and relationship to platelet-derived growth factor A and insulin-like growth factor 2 expression. Genes Chromosomes Cancer 12(2):87–96. doi:10.1002/gcc.2870120203 PubMed

Lecomte C, Andujar P, Renier A, Kheuang L, Abramowski V, Mellottee L, Fleury-Feith J, Zucman-Rossi J, Giovannini M, Jaurand MC (2005) Similar tumor suppressor gene alteration profiles in asbestos-induced murine and human mesothelioma. Cell cycle 4(12):1862–1869PubMed

Lee TC, Zhang Y, Aston C, Hintz R, Jagirdar J, Perle MA et al (1993) Normal human mesothelial cells and mesothelioma cell lines express insulin-like growth factor I and associated molecules. Cancer Res 53(12):2858–2864PubMed

Lee AY, He B, You L, Xu Z, Mazieres J, Reguart N et al (2004a) Dickkopf-1 antagonizes Wnt signaling independent of beta-catenin in human mesothelioma. Biochem Biophys Res Commun 323(4):1246–1250. doi:10.1016/j.bbrc.2004.09.001 PubMed

Lee AY, He B, You L, Dadfarmay S, Xu Z, Mazieres J et al (2004b) Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma. Oncogene 23(39):6672–6676. doi:10.1038/sj.onc.1207881 PubMed

Lee AY, Raz DJ, He B, Jablons DM (2007) Update on the molecular biology of malignant mesothelioma. Cancer 109(8):1454–1461. doi:10.1002/cncr.22552 PubMed

Lerman Y, Learman Y, Schachter P, Herceg E, Lieberman Y, Yellin A (1991) Radiation associated malignant pleural mesothelioma. Thorax 46(6):463–464PubMed

Liu Z, Klominek J (2003) Regulation of matrix metalloprotease activity in malignant mesothelioma cell lines by growth factors. Thorax 58(3):198–203. doi:10.1136/thorax.58.3.198 PubMed

Liu Z, Klominek J (2004) Chemotaxis and chemokinesis of malignant mesothelioma cells to multiple growth factors. Anticancer Res 24(3a):1625–1630PubMed

Liu Z, Ivanoff A, Klominek J (2001) Expression and activity of matrix metalloproteases in human malignant mesothelioma cell lines. Int J Cancer 91(5):638–643. doi:10.1002/1097-0215(200002)9999:9999<::AID-IJC1102>3.0.CO;2-YPubMed

Lopez-Rios F, Chuai S, Flores R, Shimizu S, Ohno T, Wakahara K et al (2006) Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res 66(6):2970–2979. doi:10.1158/0008-5472.CAN-05-3907 PubMed

Mancuso TF (1988) Relative risk of mesothelioma among railroad machinists exposed to chrysotile. Am J Ind Med 13(6):639–657. doi:10.1002/ajim.4700130604 PubMed

Manfredi JJ, Dong J, Liu WJ, Resnick-Silverman L, Qiao R, Chahinian P et al (2005) Evidence against a role for SV40 in human mesothelioma. Cancer Res 65(7):2602–2609. doi:10.1158/0008-5472.CAN-04-2461 PubMed

Marchevsky AM, Harber P, Crawford L, Wick MR (2006) Mesothelioma in patients with nonoccupational asbestos exposure. An evidence-based approach to causation assessment. Ann Diagn Pathol 10(4):241–250. doi:10.1016/j.anndiagpath.2006.06.012 PubMed

Masood R, Kundra A, Zhu S, Xia G, Scalia P, Smith DL et al (2003) Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops. Int J Cancer 104(5):603–610. doi:10.1002/ijc.10996 PubMed

Mayall F, Barratt K, Shanks J (2003) The detection of Simian virus 40 in mesotheliomas from New Zealand and England using real time FRET probe PCR protocols. J Clin Pathol 56(10):728–730. doi:10.1136/jcp.56.10.728 PubMed

McDonald JC, Armstrong BG, Edwards CW, Gibbs AR, Lloyd HM, Pooley FD et al (2001) Case-referent survey of young adults with mesothelioma: I Lung fibre analyses. Ann Occup Hyg 45(7):513–518PubMed

Mesurolle B, Qanadli SD, Merad M, Mignon F, Baldeyrou P, Tardivon A et al (2000) Unusual radiologic findings in the thorax after radiation therapy. Radiographics 20(1):67–81PubMed

Miracco C, Materno M, De Santi MM, Pirtoli L, Ninfo V (2000) Unusual second malignancies following radiation therapy: subcutaneous pleomorphic rhabdomyosarcoma and cutaneous melanoma. Two case reports. J Cutan Pathol 27(8):419–422. doi:10.1034/j.1600-0560.2000.027008419.x PubMed

Murthy SS, Testa JR (1999) Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma. J Cell Physiol 180(2):150–157. doi:10.1002/(SICI)1097-4652(199908)180:2<150::AID-JCP2>3.0.CO;2-HPubMed

Neragi-Miandoab S (2006) Multimodality approach in management of malignant pleural mesothelioma. Eur J Cardiothorac Surg 29(1):14–19. doi:10.1016/j.ejcts.2005.10.008 PubMed

Neragi-Miandoab S, Gangadharan SP, Sugarbaker DJ (2005) Cardiac sarcoma 14 years after treatment for pleural mesothelioma. N Engl J Med 352(18):1929–1930. doi:10.1056/NEJM200505053521821 PubMed

Neri M, Filiberti R, Taioli E, Garte S, Paracchini V, Bolognesi C et al (2005) Pleural malignant mesothelioma, genetic susceptibility and asbestos exposure. Mutat Res 592(1–2):36–44. doi:10.1016/j.mrfmmm.2005.06.003 PubMed

Neuberger M, Kundi M (1990) Individual asbestos exposure: smoking and mortality–a cohort study in the asbestos cement industry. Br J Ind Med 47(9):615–620PubMed

Ni Z, Liu Y, Keshava N, Zhou G, Whong W, Ong T (2000) Analysis of K-ras and p53 mutations in mesotheliomas from humans and rats exposed to asbestos. Mutat Res 468(1):87–92PubMed

Nicholson WJ (2001) The carcinogenicity of chrysotile asbestos—a review. Ind Health 39(2):57–64. doi:10.2486/indhealth.39.57 PubMed

Niggli FK, Gray TJ, Raafat F, Stevens MC (1994) Spectrum of peritoneal mesothelioma in childhood: clinical and histopathologic features, including DNA cytometry. Pediatr Hematol Oncol 11(4):399–408. doi:10.3109/08880019409140539 PubMed

Nymark P, Lindholm PM, Korpela MV, Lahti L, Ruosaari S, Kaski S et al (2007) Gene expression profiles in asbestos-exposed epithelial and mesothelial lung cell lines. BMC Genomics 8:62. doi:10.1186/1471-2164-8-62 PubMed

Ohar JA, Ampleford EJ, Howard SE, Sterling DA (2007) Identification of a mesothelioma phenotype. Respir Med 101(3):503–509. doi:10.1016/j.rmed.2006.06.028 PubMed

Oury TD, Hammar SP, Roggli VL (1998) Ultrastructural features of diffuse malignant mesotheliomas. Hum Pathol 29(12):1382–1392. doi:10.1016/S0046-8177(98)90006-5 PubMed

Papp T, Schipper H, Pemsel H, Bastrop R, Muller KM, Wiethege T et al (2001) Mutational analysis of N-ras, p53, p16INK4a, p14ARF and CDK4 genes in primary human malignant mesotheliomas. Int J Oncol 18(2):425–433PubMed

Park S, Schalling M, Bernard A, Maheswaran S, Shipley GC, Roberts D et al (1993) The Wilms tumour gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma. Nat Genet 4(4):415–420. doi:10.1038/ng0893-415 PubMed

Pass HI, Donington JS, Wu P, Rizzo P, Nishimura M, Kennedy R et al (1998) Human mesotheliomas contain the simian virus-40 regulatory region and large tumor antigen DNA sequences. J Thorac Cardiovasc Surg 116(5):854–859. doi:10.1016/S0022-5223(98)00438-3 PubMed

Pepper C, Jasani B, Navabi H, Wynford-Thomas D, Gibbs AR (1996) Simian virus 40 large T antigen (SV40LTAg) primer specific DNA amplification in human pleural mesothelioma tissue. Thorax 51(11):1074–1076PubMed

Pietruska JR, Kane AB (2007) SV40 oncoproteins enhance asbestos-induced DNA double-strand breaks and abrogate senescence in murine mesothelial cells. Cancer Res 67(8):3637–3645. doi:10.1158/0008-5472.CAN-05-3727 PubMed

Pipas JM, Levine AJ (2001) Role of T antigen interactions with p53 in tumorigenesis. Semin Cancer Biol 11(1):23–30. doi:10.1006/scbi.2000.0343 PubMed

Polakis P (2000) Wnt signaling and cancer. Genes Dev 14(15):1837–1851PubMed

Poulikakos PI, Xiao GH, Gallagher R, Jablonski S, Jhanwar SC, Testa JR (2006) Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK. Oncogene 25(44):5960–5968. doi:10.1038/sj.onc.1209587 PubMed

Pylkkanen L, Sainio M, Ollikainen T, Mattson K, Nordling S, Carpen O et al (2002) Concurrent LOH at multiple loci in human malignant mesothelioma with preferential loss of NF2 gene region. Oncol Rep 9(5):955–959PubMed

Ramos-Nino ME, Timblin CR, Mossman BT (2002) Mesothelial cell transformation requires increased AP-1 binding activity and ERK-dependent Fra-1 expression. Cancer Res 62(21):6065–6069PubMed

Riedl SJ, Shi Y (2004) Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 5(11):897–907. doi:10.1038/nrm1496 PubMed

Robinson C, van Bruggen I, Segal A, Dunham M, Sherwood A, Koentgen F et al (2006) A novel SV40 TAg transgenic model of asbestos-induced mesothelioma: malignant transformation is dose dependent. Cancer Res 66(22):10786–10794. doi:10.1158/0008-5472.CAN-05-4668 PubMed

Rosenthal GJ, Simeonova P, Corsini E (1999) Asbestos toxicity: an immunologic perspective. Rev Environ Health 14(1):11–20PubMed

Sebastien P, Janson X, Gaudichet A, Hirsch A, Bignon J (1980) Asbestos retention in human respiratory tissues: comparative measurements in lung parenchyma and in parietal pleura. IARC Sci Publ (30):237-246

Shannon VR, Nesbitt JC, Libshitz HI (1995) Malignant pleural mesothelioma after radiation therapy for breast cancer. A report of two additional patients. Cancer 76(3):437–441. doi:10.1002/1097-0142(19950801)76:3<437::AID-CNCR2820760314>3.0.CO;2-APubMed

Shaulian E, Karin M (2002) AP-1 as a regulator of cell life and death. Nat Cell Biol 4(5):E131–E136. doi:10.1038/ncb0502-e131 PubMed

Spugnini EP, Bosari S, Citro G, Lorenzon I, Cognetti F, Baldi A (2006) Human malignant mesothelioma: molecular mechanisms of pathogenesis and progression. Int J Biochem Cell Biol 38(12):2000–2004. doi:10.1016/j.biocel.2006.07.002 PubMed

Stanton MF, Wrench C (1972) Mechanisms of mesothelioma induction with asbestos and fibrous glass. J Natl Cancer Inst 48(3):797–821PubMed

Strizzi L, Catalano A, Vianale G, Orecchia S, Casalini A, Tassi G et al (2001) Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 193(4):468–475. doi:10.1002/path.824 PubMed

Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM et al (1999) Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 117(1):54–63. doi:10.1016/S0022-5223(99)70469-1 discussion 63–55PubMed

Suzuki Y (2001) Pathology of human malignant mesothelioma—preliminary analysis of 1, 517 mesothelioma cases. Ind Health 39(2):183–185. doi:10.2486/indhealth.39.183 PubMed

Testa PH Jr, Carbone M (2001) Molecular biology of mesothelioma. Lippincott, Philadelphia

Testa JR, Giordano A (2001) SV40 and cell cycle perturbations in malignant mesothelioma. Semin Cancer Biol 11(1):31–38. doi:10.1006/scbi.2000.0344 PubMed

Testa JR, Carbone M, Hirvonen A, Khalili K, Krynska B, Linnainmaa K et al (1998) A multi-institutional study confirms the presence and expression of simian virus 40 in human malignant mesotheliomas. Cancer Res 58(20):4505–4509PubMed

Thurlbeck WMR (1988) The respiratory system, disease of the pleura. Lippincott, Philadelphia

Toyooka S, Carbone M, Toyooka KO, Bocchetta M, Shivapurkar N, Minna JD et al (2002) Progressive aberrant methylation of the RASSF1A gene in simian virus 40 infected human mesothelial cells. Oncogene 21(27):4340–4344. doi:10.1038/sj.onc.1205381 PubMed

Uematsu K, Kanazawa S, You L, He B, Xu Z, Li K et al (2003) Wnt pathway activation in mesothelioma: evidence of Dishevelled overexpression and transcriptional activity of beta-catenin. Cancer Res 63(15):4547–4551PubMed

Vanneuville G, Escande G, Dechelotte P, Demeocq F, Nebout P, Scheye T et al (1993) Malignant pleural tumor in a child mimicking a mesothelioma. Eur J Pediatr Surg 3(6):362–365PubMedCrossRef

Vaslet CA, Messier NJ, Kane AB (2002) Accelerated progression of asbestos-induced mesotheliomas in heterozygous p53± mice. Toxicol Sci 68(2):331–338. doi:10.1093/toxsci/68.2.331 PubMed

Versnel MA, Hagemeijer A, Bouts MJ, van der Kwast TH, Hoogsteden HC (1988) Expression of c-sis (PDGF B-chain) and PDGF A-chain genes in ten human malignant mesothelioma cell lines derived from primary and metastatic tumors. Oncogene 2(6):601–605PubMed

Vilchez RA, Kozinetz CA, Arrington AS, Madden CR, Butel JS (2003) Simian virus 40 in human cancers. Am J Med 114(8):675–684. doi:10.1016/S0002-9343(03)00087-1 PubMed

Vivo C, Lecomte C, Levy F, Leroy K, Kirova Y, Renier A et al (2003) Cell cycle checkpoint status in human malignant mesothelioma cell lines: response to gamma radiation. Br J Cancer 88(3):388–395. doi:10.1038/sj.bjc.6600736 PubMed

Weissmann LB, Corson JM, Neugut AI, Antman KH (1996) Malignant mesothelioma following treatment for Hodgkin’s disease. J Clin Oncol 14(7):2098–2100PubMed

Whitmarsh AJ, Davis RJ (1996) Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J Mol Med 74(10):589–607. doi:10.1007/s001090050063 PubMed

Whitson BA, Kratzke RA (2006) Molecular pathways in malignant pleural mesothelioma. Cancer Lett 239(2):183–189. doi:10.1016/j.canlet.2005.08.010 PubMed

Wojta J, Kaun C, Breuss JM, Koshelnick Y, Beckmann R, Hattey E, Mildner M, Weninger W, Nakamura T, Tschachler E et al (1999) Hepatocyte growth factor increases expression of vascular endothelial growth factor and plasminogen activator inhibitor-1 in human keratinocytes and the vascular endothelial growth factor receptor flk-1 in human endothelial cells. Lab Investig 79(4):427–438PubMed

Wong L, Zhou J, Anderson D, Kratzke RA (2002) Inactivation of p16INK4a expression in malignant mesothelioma by methylation. Lung Cancer 38(2):131–136. doi:10.1016/S0169-5002(02)00178-2 PubMed

Report on the expert panel on health effects of asbestos and synthetic vitreous fibers: the influence of fiber length. http://www.atsdr.cdc.gov/HAC/asbestospanel/finalpart1.pdf

Yang H, Bocchetta M, Kroczynska B, Elmishad AG, Chen Y, Liu Z et al (2006) TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci USA 103(27):10397–10402. doi:10.1073/pnas.0604008103 PubMed

Yarborough CM (2006) Chrysotile as a cause of mesothelioma: an assessment based on epidemiology. Crit Rev Toxicol 36(2):165–187. doi:10.1080/10408440500534248 PubMed

Yarborough CM (2007) The risk of mesothelioma from exposure to chrysotile asbestos. Curr Opin Pulm Med 13(4):334–338. doi:10.1097/MCP.0b013e328121446c PubMed

Zanella CL, Posada J, Tritton TR, Mossman BT (1996) Asbestos causes stimulation of the extracellular signal-regulated kinase 1 mitogen-activated protein kinase cascade after phosphorylation of the epidermal growth factor receptor. Cancer Res 56(23):5334–5338PubMed

Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB, De Marzo AM (2004) Cyclooxygenases in cancer: progress and perspective. Cancer Lett 215(1):1–20. doi:10.1016/j.canlet.2004.06.014 PubMed

Zhong J, Gencay MM, Bubendorf L, Burgess JK, Parson H, Robinson BW et al (2006) ERK1/2 and p38 MAP kinase control MMP-2, MT1-MMP, and TIMP action and affect cell migration: a comparison between mesothelioma and mesothelial cells. J Cell Physiol 207(2):540–552. doi:10.1002/jcp.20605 PubMed

Titel: Pathogenesis of malignant pleural mesothelioma and the role of environmental and genetic factors
verfasst von: Shoshana J. Weiner
Siyamek Neragi-Miandoab
Publikationsdatum: 01.01.2009
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 1/2009
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-008-0444-9

Neu im Fachgebiet Onkologie

16.04.2024 | Maligne primäre ZNS-Tumoren | Nachrichten

Springer Medizin

Pathogenesis of malignant pleural mesothelioma and the role of environmental and genetic factors

Abstract

Background

Methods

Conclusion

Neu im Fachgebiet Onkologie

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Das Ende der vollständigen axillären Lymphknotendissektion

Update Onkologie

Springer Medizin

Abstract

Background

Methods

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2009

Loss of WWOX expression in human extrahepatic cholangiocarcinoma

Pre-treatment global quality of health predicts progression free survival in metastatic kidney cancer patients treated with sorafenib or sunitinib

Survivin gene-expression and splicing isoforms in oral squamous cell carcinoma

Evolutionary maintenance of oncogenesis

Cutaneous metastases of visceral tumours: a review

Prognostic relevance of glucosylceramide synthase (GCS) expression in breast cancer

Neu im Fachgebiet Onkologie

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Das Ende der vollständigen axillären Lymphknotendissektion

Update Onkologie